$ 299.99 USD $ 299.99 USD RX ONLY Inquire for Pricing $ 299.99 USD Injection GLP-1/GIP + B6 supports appetite awareness, metabolic balance, energy support, and overall wellness with added B6 support
When experimenting with DSIP, track objective changes across the following biomarkers: Sleep latency (i.e
However, many peptide products promoted online are unapproved and can carry serious risks
Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]
Yan H, Jia H, Wang X, Gao H, Guo X, Xu B